DRG Epidemiology’s coverage of neuropathic back pain (NBP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of NBP for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered.

DRG Epidemiology’s NBP forecast will answer the following questions:

  • Of all people with NBP, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with NBP, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NBP over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

Table of contents

  • Neuropathic Back Pain - Epidemiology - Europe
    • Introduction
      • Key Findings
      • Total Prevalence of Neuropathic Back Pain per 100 People Aged 20+ in 2018
      • Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Neuropathic Back Pain over the Next 20 Years
    • Epidemiology Data
    • Methods
      • Total Prevalent Cases
      • Diagnosed Prevalent Cases
      • Drug-Treated Cases
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Neuropathic Back Pain
        • Studies Excluded from the Analysis of Neuropathic Back Pain
      • Risk/Protective Factors
        • Risk/Protective Factors for Neuropathic Back Pain
      • Bibliography

Author(s): Mudasir Khan, M.P.H.; Abey John, M.P.H.

Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai.

Abey John, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing family planning health programs in India in collaboration with the government of India. He also has worked at the grassroots level as a health team manager to help the rural population living in the foothills of the Himalayas. He holds a master’s degree in public health.

 


Related Reports

Neuropathic Pain - Landscape & Forecast - Disease Landscape & Forecast

The treatment of neuropathic pain involves the use of drugs from several drug classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid a...

View Details